Thyroid Cancer
📧 Sign up to get email alerts when something new happens for Thyroid Cancer.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2021-05-11Clinical Trial Update: Minimizing Narcotic Analgesics After Endocrine Surgery [Phase 4]
Phase 4 trial updating strategies to minimize narcotic analgesics after endocrine surgery for thyroid-related conditions.
-
CLINICAL_TRIALS trial_result · 2021-04-01Clinical Trial Update: Anlotinib Neoadjuvant Treatment in Locally Advanced Thyroid Cancer [Phase 2]
Phase 2 clinical trial update for anlotinib as neoadjuvant treatment in locally advanced thyroid cancer.
-
CLINICAL_TRIALS trial_result · 2021-03-05Clinical Trial Update: Clinical Trial in RAI-Refractory Thyroid Carcinoma Evaluating BRAF & MEK Blockade for Re-differentiation Therapy [Phase 2]
Phase 2 trial evaluating BRAF and MEK blockade as a re-differentiation therapy for RAi-refractory thyroid carcinoma is ongoing and status is…
-
CLINICAL_TRIALS trial_result · 2021-01-22Clinical Trial Update: Adaptive Tyrosine Kinase Inhibitor (TKI) Therapy In Patients With Thyroid Cancer [Phase 2]
Phase 2 adaptive TKI therapy trial in thyroid cancer was terminated; results posted previously.
-
CLINICAL_TRIALS trial_result · 2020-12-01Clinical Trial Update: Levothyroxine Replacement With Liquid Gel Capsules vs Tablets Post-thyroidectomy [Phase 4]
Phase 4 trial comparing liquid gel capsule levothyroxine to standard tablets after thyroidectomy; study terminated with post results posted.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2020-11-05FDA Approved: LEVOTHYROXINE SODIUM — Supplemental Application (Mylan Pharmaceuticals Inc.)
The FDA approved a supplemental application for Levothyroxine Sodium from Mylan Pharmaceuticals under an ANDA, authorizing the change descri…
-
CLINICAL_TRIALS trial_result · 2020-11-03Clinical Trial Update: Camrelizumab and Apatinib for Neoadjuvant Therapy in Thyroid Cancer [Phase 2]
Phase 2 clinical trial update on camrelizumab and apatinib as neoadjuvant therapy for thyroid cancer.
-
FDA approval · 2020-09-04FDA Approved: GAVRETO — Original Application (Genentech, Inc.)
The FDA approved Gavreto (pralsetinib) from Genentech as an original application for treating metastatic RET fusion-positive cancers, includ…
-
CLINICAL_TRIALS trial_result · 2020-08-25Clinical Trial Update: Pasireotide & Everolimus in Adult Patients With Radioiodine-Refractory Differentiated & Medullary Thyroid Cancer [Phase 2]
Phase 2 trial evaluating pasireotide plus everolimus in adult patients with radioiodine-refractory differentiated and medullary thyroid canc…
-
CLINICAL_TRIALS trial_result · 2020-08-24Clinical Trial Update: Toripalimab Combined With Surufatinib for Locally Advanced Thyroid Cancer: a Phase II Study [Phase 2]
A Phase II study evaluating toripalimab in combination with surufatinib for locally advanced thyroid cancer is ongoing, with no stated statu…
-
CLINICAL_TRIALS trial_result · 2020-08-14Clinical Trial Update: A Study of E7080 in Subjects With Advanced Thyroid Cancer [Phase 2]
Phase 2 trial update for E7080 in advanced thyroid cancer has completed with results posted.
-
CLINICAL_TRIALS trial_result · 2020-03-27Clinical Trial Update: Diagnostic Accuracy Study of Indocyanine Green for Parathyroid Perfusion Assessment [Phase 4]
Phase 4 diagnostic accuracy study evaluating indocyanine green for assessing parathyroid perfusion in thyroid surgery is completed.
-
FDA approval · 2020-03-12FDA Approved: THYROGEN — Supplemental Application (Genzyme Corporation)
FDA approved a supplemental application for THYROGEN (thyrotropin alfa) from Genzyme Corporation, updating the labeling to support its use i…
-
CLINICAL_TRIALS trial_result · 2020-02-26Clinical Trial Update: Pazopanib Hydrochloride in Treating Patients With Advanced Thyroid Cancer [Phase 2]
Phase 2 trial update of pazopanib hydrochloride for advanced thyroid cancer shows results post-completion.
-
FDA approval · 2020-02-05FDA Approved: SODIUM IODIDE I-131 — Original Application (Radnostix, Inc.)
FDA approved the original application for Sodium Iodide I-131 (Radnostix, Inc.), a radiopharmaceutical used to treat hyperthyroidism and thy…
-
CLINICAL_TRIALS trial_result · 2019-12-27Clinical Trial Update: Inolitazone Dihydrochloride and Paclitaxel in Treating Patients With Advanced Anaplastic Thyroid Cancer [Phase 2]
Phase 2 trial results for the combination of inolitazone dihydrochloride and paclitaxel in advanced anaplastic thyroid cancer; the update re…
-
CLINICAL_TRIALS trial_result · 2019-11-27Clinical Trial Update: Study of Neoadjuvant Regimen for Radioactive Iodine Treatment of Metastatic and Advanced Differentiated Thyroid Cancers [Phase 2]
Phase 2 trial evaluating a neoadjuvant regimen for radioactive iodine treatment in metastatic and advanced differentiated thyroid cancers; s…
-
CLINICAL_TRIALS trial_result · 2019-11-25Clinical Trial Update: A Study of Alectinib in RET-rearranged Non-small Cell Lung Cancer or RET-mutated Thyroid Cancer [Phase 1, Phase 2]
Clinical trial update for alectinib in RET-rearranged non-small cell lung cancer and RET-mutated thyroid cancer; study terminated with resul…
-
CLINICAL_TRIALS trial_result · 2019-11-13Clinical Trial Update: Safety and Efficacy of Sorafenib in Patients With Advanced Thyroid Cancer: a Phase II Clinical Study [Phase 2]
Phase II study reporting safety and efficacy of sorafenib in patients with advanced thyroid cancer completed.
-
CLINICAL_TRIALS trial_result · 2019-08-01Clinical Trial Update: Evaluating the Safety and Efficacy of Oral Lenvatinib in Medullary and Iodine-131 Refractory, Unresectable Differentiated Thyroid Cancers, Stratified by Histology [Phase 2]
Phase 2 trial evaluating safety and efficacy of oral lenvatinib in medullary and iodine-131 refractory, unresectable differentiated thyroid …
-
CLINICAL_TRIALS trial_result · 2019-06-11Clinical Trial Update: Efficacy of Radium 223 in Radioactive Iodine Refractory Bone Metastases From Differentiated Thyroid Cancer [Phase 2]
Phase 2 clinical trial update evaluating efficacy of Radium 223 in radioactive iodine-refractory bone metastases from differentiated thyroid…
-
FDA approval · 2019-06-03FDA Approved: LEVOTHYROXINE SODIUM — Supplemental Application (Lupin Pharmaceuticals, Inc.)
FDA approved a supplemental application for Levothyroxine Sodium from Lupin Pharmaceuticals, Inc. This action updates the product's labeling…
-
FDA approval · 2019-04-23FDA Approved: LEVOTHYROXINE SODIUM — Supplemental Application (Alvogen, Inc.)
FDA approved a supplemental application for Levothyroxine Sodium (Alvogen, Inc.), authorizing changes to the product labeling.
-
CLINICAL_TRIALS trial_result · 2019-02-22Clinical Trial Update: The Effects of T4 Versus T4/T3 on Psychological Distress After Total Thyroidectomy in Thyroid Cancer Patients [NA]
This update reports the completion of a trial comparing levothyroxine (T4) monotherapy with a combination levothyroxine/liothyronine (T4/T3)…
-
CLINICAL_TRIALS trial_result · 2018-11-02Clinical Trial Update: Recombinant Thyrotropin PET-CT Fusion Scanning in Thyroid Cancer [Phase 2]
Phase 2 trial evaluating recombinant thyrotropin–PET-CT fusion scanning in thyroid cancer has completed with results posted.